|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
EP2041756B1
(en)
|
2006-07-14 |
2015-05-13 |
FEI Company |
A multi-source plasma focused ion beam system
|
|
KR20100014588A
(ko)
*
|
2007-02-27 |
2010-02-10 |
제넨테크, 인크. |
길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
|
|
US20090309617A1
(en)
*
|
2007-08-24 |
2009-12-17 |
Ye Fang |
Biosensor antibody functional mapping
|
|
WO2009141239A1
(en)
*
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
|
US8518405B2
(en)
*
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
HRP20251657T1
(hr)
|
2009-12-14 |
2026-02-13 |
Ablynx N.V. |
Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
|
|
WO2012015696A1
(en)
*
|
2010-07-26 |
2012-02-02 |
Baylor Research Institute |
Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
|
|
LT2609118T
(lt)
|
2010-08-23 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antikūnai ir jų panaudojimo būdai
|
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
NO2699601T3
(cg-RX-API-DMAC10.html)
*
|
2011-04-21 |
2018-06-16 |
|
|
|
JP6038920B2
(ja)
*
|
2011-08-23 |
2016-12-07 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
抗ｏｘ４０抗体およびそれを使用する方法
|
|
DK3043810T3
(da)
|
2013-09-09 |
2020-01-27 |
Canimguide Therapeutics Ab |
Immunsystemsmodulatorer
|
|
GB201403775D0
(en)
*
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
JP2017165652A
(ja)
*
|
2014-06-30 |
2017-09-21 |
国立大学法人東北大学 |
新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
|
|
CN107074951B
(zh)
*
|
2014-08-04 |
2021-08-03 |
贝勒研究院 |
拮抗性抗-ox40l抗体及其使用方法
|
|
US11554181B2
(en)
|
2014-09-05 |
2023-01-17 |
The University Of North Carolina At Charlotte |
Tumor specific antibody conjugates and uses therefor
|
|
US9434785B1
(en)
*
|
2015-04-30 |
2016-09-06 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
|
US9512229B2
(en)
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
PL3265123T3
(pl)
*
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Przeciwciała, zastosowania i sposoby
|
|
WO2016144650A1
(en)
|
2015-03-06 |
2016-09-15 |
Canimguide Therapeutics Ab |
Immune system modulators and compositions
|
|
EP3292152A1
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
WO2017096179A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
DE102016105069A1
(de)
|
2016-03-18 |
2017-09-21 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Antivirale Immuntherapie durch Membranrezeptorligation
|
|
AU2016402264B2
(en)
*
|
2016-04-15 |
2024-08-22 |
Pontificia Universidad Católica De Chile |
Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
RU2764548C2
(ru)
|
2016-08-09 |
2022-01-18 |
Кимаб Лимитед |
Анти-icos антитела
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
US12605469B2
(en)
|
2017-10-02 |
2026-04-21 |
The University Of North Carolina At Charlotte |
Tumor specific antibody conjugates and uses therefor
|
|
CA3084394A1
(en)
|
2017-11-24 |
2019-05-31 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-ox40 antibodies and uses thereof
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB202012331D0
(en)
*
|
2020-08-07 |
2020-09-23 |
Petmedix Ltd |
Therapeutic antibodies
|
|
CN114437228B
(zh)
*
|
2020-10-30 |
2024-02-06 |
中国科学院生物物理研究所 |
一种il-2与抗体亚单位构成的双功能融合蛋白
|
|
AU2020480890B2
(en)
*
|
2020-12-09 |
2026-07-02 |
Hk Inno.N Corporation |
ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFα BISPECIFIC ANTIBODY, AND USES THEREOF
|
|
TWI905133B
(zh)
*
|
2020-12-09 |
2025-11-21 |
南韓商怡諾安有限公司 |
抗-OX40L抗體、抗OX40L和抗-TNFα雙特異性抗體及其用途
|
|
MX2024001877A
(es)
*
|
2021-08-10 |
2024-02-28 |
Kymab Ltd |
Tratamiento de dermatitis atopica.
|
|
WO2023152486A1
(en)
*
|
2022-02-09 |
2023-08-17 |
Petmedix Ltd |
Therapeutic antibodies
|
|
AU2024369195A1
(en)
*
|
2023-10-23 |
2026-05-07 |
Abcellera Biologics Inc. |
Anti-ox40l antibodies and methods of use
|
|
TW202540204A
(zh)
*
|
2024-01-26 |
2025-10-16 |
西班牙商阿爾米雷爾有限公司 |
雙特異性分子及使用其的治療方法
|
|
WO2026112418A2
(en)
*
|
2024-11-22 |
2026-05-28 |
Apogee Therapeutics, Inc. |
Ox40l antibody formulation
|